Details of the Drug

General Information of Drug (ID: DMK54YG)

Drug Name
Griseofulvin
Synonyms
Amudane; Delmofulvina; Fulcin; Fulcine; Fulvicin; FulvicinUF; Fulvina; Fulvinil; Fulvistatin; Fungivin; Greosin;Gresfeed; Gricin; Grifulin; Grifulvin; GrisPEG; Grisactin; Griscofulvin; Grisefuline; Griseo; Griseofulvina; Griseofulvine; Griseofulvinum; Griseomix; Griseostatin; Grisetin; Grisofulvin; Grisovin; Grizeofulvin; Grysio; Guservin; Lamoryl; Likuden; Likunden; Murfulvin; Poncyl; Spirofulvin; Sporostatin; Xuanjing; Curling fact or; Curling factor; Fulvican grisactin; Fulvicin U F; Grifulvin V; Gris PEG; Grisactin Ultra; Grise ostatin; Griseofulvin forte; Grisovin FP; Interacts with polymerized microtubules and associated proteins; Sporostatin xan; Biogrisin-FP; FULVICIN P/G 165; FULVICIN P/G 330;Fulvicin Bolus (Veterinary); Fulvicin P/G; Fulvicin U/F; Fulvidex (Veterinary); GRISEOFULVIN, MICROCRYSTALLINE; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; Gris-PEG; Griseofulvin and Alpha-IFN; Griseofulvin-forte; Griseofulvina [INN-Spanish]; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]; Grisovin (TN); NP-002466; Neo-Fulcin; ULTRAGRIS-165; ULTRAGRIS-330; USAF SC-2; Fulvicin-P/G; Fulvicin-U-F; Fulvicin-U/F; Fulvicin-U/F (Veterinary); Griseofulvin [USAN:INN:BAN:JAN]; (+)-Griseofulvin; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione
Indication
Disease Entry ICD 11 Status REF
Onychomycosis EE12.1 Approved [1]
Ringworm infection 1F28 Approved [2]
Tinea corporis 1F28.Y Approved [1]
Tinea cruris 1F28.3 Approved [1]
Tinea pedis 1F28.2 Investigative [1]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 352.8
Logarithm of the Partition Coefficient (xlogp) 2.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
0.3% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 9 - 21 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 35.43341 micromolar/kg/day [5]
Chemical Identifiers
Formula
C17H17ClO6
IUPAC Name
(2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
Canonical SMILES
C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
InChI
InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1
InChIKey
DDUHZTYCFQRHIY-RBHXEPJQSA-N
Cross-matching ID
PubChem CID
441140
ChEBI ID
CHEBI:27779
CAS Number
126-07-8
DrugBank ID
DB00400
TTD ID
D0C1SF
INTEDE ID
DR0791
ACDINA ID
D00306
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fungal Microtubule (Fung MicroTU) TT7PBUD NOUNIPROTAC Inducer [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [9]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Gene/Protein Processing [9]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [10]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Gene/Protein Processing [9]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Gene/Protein Processing [11]
L-selectin (SELL) OT6RAJZR LYAM1_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Griseofulvin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Increased metabolism of Griseofulvin caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [13]
Midostaurin DMI6E0R Moderate Increased metabolism of Griseofulvin caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Gilteritinib DMTI0ZO Moderate Increased metabolism of Griseofulvin caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Oliceridine DM6MDCF Moderate Increased metabolism of Griseofulvin caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [16]
Donepezil DMIYG7Z Moderate Increased metabolism of Griseofulvin caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [17]
Ivabradine DM0L594 Moderate Increased metabolism of Griseofulvin caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [18]
Dronedarone DMA8FS5 Moderate Increased metabolism of Griseofulvin caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [19]
Bedaquiline DM3906J Moderate Increased metabolism of Griseofulvin caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [20]
Buspirone DMBS632 Moderate Increased metabolism of Griseofulvin caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [21]
Methylphenobarbital DMDSWAG Moderate Altered absorption of Griseofulvin caused by Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [22]
Voriconazole DMAOL2S Moderate Increased metabolism of Griseofulvin caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [23]
Montelukast DMD157S Moderate Increased metabolism of Griseofulvin caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [24]
Telithromycin DMZ4P3A Moderate Increased metabolism of Griseofulvin caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Griseofulvin caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Lapatinib DM3BH1Y Moderate Increased metabolism of Griseofulvin caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
LY2835219 DM93VBZ Moderate Increased metabolism of Griseofulvin caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Exemestane DM9HPW3 Moderate Increased metabolism of Griseofulvin caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Griseofulvin caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Tucatinib DMBESUA Moderate Increased metabolism of Griseofulvin caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Palbociclib DMD7L94 Moderate Increased metabolism of Griseofulvin caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Alpelisib DMEXMYK Moderate Increased metabolism of Griseofulvin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Griseofulvin caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Griseofulvin caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Griseofulvin caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Toremifene DMQYUWG Moderate Increased metabolism of Griseofulvin caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Bosutinib DMTI8YE Moderate Increased metabolism of Griseofulvin caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Estradiol DMUNTE3 Moderate Increased metabolism of Griseofulvin caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Atorvastatin DMF28YC Moderate Increased metabolism of Griseofulvin caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [37]
Macitentan DMP79A1 Moderate Increased metabolism of Griseofulvin caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [38]
Secobarbital DM14RF5 Moderate Altered absorption of Griseofulvin caused by Secobarbital. Chronic insomnia [7A00] [22]
Anisindione DM2C48U Moderate Increased metabolism of Griseofulvin caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [39]
Irinotecan DMP6SC2 Moderate Increased metabolism of Griseofulvin caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [40]
Drospirenone DM1A9W3 Major Increased metabolism of Griseofulvin caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [41]
Levonorgestrel DM1DP7T Major Increased metabolism of Griseofulvin caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [41]
Ulipristal DMBNI20 Moderate Increased metabolism of Griseofulvin caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [18]
Norgestimate DMYP4XC Major Increased metabolism of Griseofulvin caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [42]
Levobupivacaine DM783CH Minor Increased metabolism of Griseofulvin caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [43]
Methohexital DM7YMIT Moderate Altered absorption of Griseofulvin caused by Methohexital. Corneal disease [9A76-9A78] [22]
Alfentanil DMVO0UB Moderate Increased metabolism of Griseofulvin caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [44]
Mifepristone DMGZQEF Moderate Increased metabolism of Griseofulvin caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [45]
Ivacaftor DMZC1HS Moderate Increased metabolism of Griseofulvin caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [46]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Griseofulvin caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [47]
Aprepitant DM053KT Moderate Increased metabolism of Griseofulvin caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [48]
Vortioxetine DM6F1PU Moderate Increased metabolism of Griseofulvin caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [49]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Griseofulvin caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [50]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Griseofulvin caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [42]
Zonisamide DM0DTF7 Moderate Increased metabolism of Griseofulvin caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Primidone DM0WX6I Moderate Altered absorption of Griseofulvin caused by Primidone. Epilepsy/seizure [8A61-8A6Z] [22]
Stiripentol DMMSDOY Moderate Increased metabolism of Griseofulvin caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Phenobarbital DMXZOCG Moderate Altered absorption of Griseofulvin caused by Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [22]
Carbamazepine DMZOLBI Moderate Increased metabolism of Griseofulvin caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [52]
Praziquantel DMOU1PK Moderate Increased metabolism of Griseofulvin caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [53]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Griseofulvin caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [54]
Tazemetostat DMWP1BH Moderate Increased metabolism of Griseofulvin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [55]
Solifenacin DMG592Q Moderate Increased metabolism of Griseofulvin caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [56]
Mirabegron DMS1GYT Minor Increased metabolism of Griseofulvin caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [57]
Darifenacin DMWXLYZ Moderate Increased metabolism of Griseofulvin caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [58]
Caspofungin DMGQIPT Moderate Increased metabolism of Griseofulvin caused by Caspofungin mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [59]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of Griseofulvin and Ketoconazole. Fungal infection [1F29-1F2F] [27]
Ripretinib DM958QB Moderate Increased metabolism of Griseofulvin caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [27]
Sunitinib DMCBJSR Moderate Increased metabolism of Griseofulvin caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [27]
Avapritinib DMK2GZX Moderate Increased metabolism of Griseofulvin caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [18]
Ergotamine DMKR3C5 Moderate Increased metabolism of Griseofulvin caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [27]
Boceprevir DMBSHMF Moderate Increased metabolism of Griseofulvin caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [60]
MK-1439 DM215WE Moderate Increased metabolism of Griseofulvin caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Delavirdine DM3NF5G Moderate Increased metabolism of Griseofulvin caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [62]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Griseofulvin caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Fostemsavir DM50ILT Minor Increased metabolism of Griseofulvin caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Tipranavir DM8HJX6 Moderate Increased metabolism of Griseofulvin caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Efavirenz DMC0GSJ Moderate Increased metabolism of Griseofulvin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Dolutegravir DMCZGRE Minor Increased metabolism of Griseofulvin caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Saquinavir DMG814N Moderate Increased metabolism of Griseofulvin caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Etravirine DMGV8QU Moderate Increased metabolism of Griseofulvin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Griseofulvin caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Amprenavir DMLMXE0 Moderate Increased metabolism of Griseofulvin caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Darunavir DMN3GCH Moderate Increased metabolism of Griseofulvin caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Atazanavir DMSYRBX Moderate Increased metabolism of Griseofulvin caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Maraviroc DMTL94F Moderate Increased metabolism of Griseofulvin caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Ritonavir DMU764S Moderate Increased metabolism of Griseofulvin caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Tolvaptan DMIWFRL Moderate Increased metabolism of Griseofulvin caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [18]
Suvorexant DM0E6S3 Moderate Increased metabolism of Griseofulvin caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [68]
Amobarbital DM0GQ8N Moderate Altered absorption of Griseofulvin caused by Amobarbital. Insomnia [7A00-7A0Z] [22]
Ramelteon DM7IW9J Moderate Increased metabolism of Griseofulvin caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [69]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Griseofulvin caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [70]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Griseofulvin caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [71]
ITI-007 DMUQ1DO Major Increased metabolism of Griseofulvin caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [72]
Zolpidem DMWOSKJ Moderate Increased metabolism of Griseofulvin caused by Zolpidem mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Naloxegol DML0B41 Moderate Increased metabolism of Griseofulvin caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [73]
Pemigatinib DM819JF Moderate Increased metabolism of Griseofulvin caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [18]
Crizotinib DM4F29C Moderate Increased metabolism of Griseofulvin caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [74]
Brigatinib DM7W94S Moderate Increased metabolism of Griseofulvin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [27]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Griseofulvin and Porfimer Sodium. Lung cancer [2C25] [75]
Erlotinib DMCMBHA Moderate Increased metabolism of Griseofulvin caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Griseofulvin caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [77]
Osimertinib DMRJLAT Moderate Increased metabolism of Griseofulvin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [78]
Capmatinib DMYCXKL Moderate Increased metabolism of Griseofulvin caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [79]
Selpercatinib DMZR15V Moderate Increased metabolism of Griseofulvin caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Artemether DM48QOT Moderate Increased metabolism of Griseofulvin caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [27]
Quinine DMSWYF5 Moderate Increased metabolism of Griseofulvin caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [80]
Idelalisib DM602WT Moderate Increased metabolism of Griseofulvin caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [81]
GDC-0199 DMH0QKA Moderate Increased metabolism of Griseofulvin caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [82]
IPI-145 DMWA24P Moderate Increased metabolism of Griseofulvin caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [83]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Griseofulvin caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [84]
Ibrutinib DMHZCPO Moderate Increased metabolism of Griseofulvin caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [85]
Vincristine DMINOX3 Moderate Increased metabolism of Griseofulvin caused by Vincristine mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [86]
Ponatinib DMYGJQO Moderate Increased metabolism of Griseofulvin caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [27]
Vemurafenib DM62UG5 Moderate Increased metabolism of Griseofulvin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [87]
Selumetinib DMC7W6R Moderate Increased metabolism of Griseofulvin caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [88]
LGX818 DMNQXV8 Moderate Increased metabolism of Griseofulvin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [89]
Estrone DM5T6US Moderate Increased metabolism of Griseofulvin caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [30]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Griseofulvin caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [42]
Ubrogepant DM749I3 Moderate Increased metabolism of Griseofulvin caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [90]
Flibanserin DM70DTN Moderate Increased metabolism of Griseofulvin caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [91]
Panobinostat DM58WKG Moderate Increased metabolism of Griseofulvin caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [92]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Griseofulvin and Methoxsalen. Mycosis fungoides [2B01] [27]
Nilotinib DM7HXWT Moderate Increased metabolism of Griseofulvin caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [93]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Griseofulvin caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [94]
Imatinib DM7RJXL Moderate Increased metabolism of Griseofulvin caused by Imatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [95]
Modafinil DMYILBE Moderate Increased metabolism of Griseofulvin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [96]
Rolapitant DM8XP26 Moderate Increased metabolism of Griseofulvin caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [97]
E-2007 DMJDYNQ Moderate Increased metabolism of Griseofulvin caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [18]
Entrectinib DMMPTLH Moderate Increased metabolism of Griseofulvin caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [98]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Griseofulvin caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [99]
Olaparib DM8QB1D Moderate Increased metabolism of Griseofulvin caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [27]
Butorphanol DM5KYPJ Moderate Increased metabolism of Griseofulvin caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [16]
Aspirin DM672AH Minor Altered absorption of Griseofulvin caused by Aspirin. Pain [MG30-MG3Z] [100]
Buprenorphine DMPRI8G Moderate Increased metabolism of Griseofulvin caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [101]
Hydrocodone DMQ2JO5 Moderate Increased metabolism of Griseofulvin caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [16]
Oxycodone DMXLKHV Moderate Increased metabolism of Griseofulvin caused by Oxycodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [16]
Pimavanserin DMR7IVC Moderate Increased metabolism of Griseofulvin caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [102]
Macimorelin DMQYJIR Moderate Increased metabolism of Griseofulvin caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [103]
Lefamulin DME6G97 Moderate Increased metabolism of Griseofulvin caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [104]
Ergonovine DM0VEC1 Moderate Increased metabolism of Griseofulvin caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [27]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Griseofulvin caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [105]
Enzalutamide DMGL19D Moderate Increased metabolism of Griseofulvin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [106]
Darolutamide DMV7YFT Moderate Increased metabolism of Griseofulvin caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [107]
Silodosin DMJSBT6 Moderate Increased metabolism of Griseofulvin caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [27]
Apremilast DMTWS9E Moderate Increased metabolism of Griseofulvin caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [108]
Everolimus DM8X2EH Moderate Increased metabolism of Griseofulvin caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [27]
Axitinib DMGVH6N Moderate Increased metabolism of Griseofulvin caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [109]
Temsirolimus DMS104F Moderate Increased metabolism of Griseofulvin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [27]
Tofacitinib DMBS370 Moderate Increased metabolism of Griseofulvin caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [27]
Quetiapine DM1N62C Moderate Increased metabolism of Griseofulvin caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [27]
Aripiprazole DM3NUMH Moderate Increased metabolism of Griseofulvin caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [110]
Fentanyl DM8WAHT Moderate Increased metabolism of Griseofulvin caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [16]
Avanafil DM75CXN Moderate Increased metabolism of Griseofulvin caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [111]
Tadalafil DMJZHT1 Moderate Increased metabolism of Griseofulvin caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [18]
LDE225 DMM9F25 Moderate Increased metabolism of Griseofulvin caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [112]
Larotrectinib DM26CQR Moderate Increased metabolism of Griseofulvin caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Vinblastine DM5TVS3 Moderate Increased metabolism of Griseofulvin caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [86]
Docetaxel DMDI269 Moderate Increased metabolism of Griseofulvin caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [113]
Trabectedin DMG3Y89 Moderate Increased metabolism of Griseofulvin caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Armodafinil DMGB035 Moderate Increased metabolism of Griseofulvin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [96]
LEE011 DMMX75K Moderate Increased metabolism of Griseofulvin caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Norethindrone DMTY169 Major Increased metabolism of Griseofulvin caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [42]
Taxol DMUOT9V Moderate Increased metabolism of Griseofulvin caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [114]
Doxorubicin DMVP5YE Moderate Increased metabolism of Griseofulvin caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Warfarin DMJYCVW Moderate Increased metabolism of Griseofulvin caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [39]
Fostamatinib DM6AUHV Moderate Increased metabolism of Griseofulvin caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [115]
Apixaban DM89JLN Moderate Increased metabolism of Griseofulvin caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [116]
Brilinta DMBR01X Moderate Increased metabolism of Griseofulvin caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [117]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Griseofulvin caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [118]
Sirolimus DMGW1ID Moderate Increased metabolism of Griseofulvin caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [27]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Griseofulvin caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [27]
Liraglutide DM3FXPS Minor Altered absorption of Griseofulvin due to GI dynamics variation caused by Liraglutide. Type 2 diabetes mellitus [5A11] [119]
Saxagliptin DMGXENV Moderate Increased metabolism of Griseofulvin caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [120]
Linagliptin DMWFJTR Moderate Increased metabolism of Griseofulvin caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [121]
Elagolix DMB2C0E Moderate Increased metabolism of Griseofulvin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [122]
⏷ Show the Full List of 168 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
methylparaben E00149 7456 Antimicrobial preservative
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben E00543 23663626 Antimicrobial preservative
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate E00294 24441 Diluent
Calcium stearate E00244 15324 lubricant
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Griseofulvin 125 mg tablet 125 mg Oral Tablet Oral
Griseofulvin 250 mg tablet 250 mg Oral Tablet Oral
Griseofulvin 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Griseofulvin FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Dermatophyte infections. Am Fam Physician. 2003 Jan 1;67(1):101-8.
7 Kinetic mechanism of the activation of human plasminogen by streptokinase. Biochemistry. 1975 Oct 7;14(20):4459-65.
8 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
9 The anti-mitotic drug griseofulvin induces apoptosis of human germ cell tumor cells through a connexin 43-dependent molecular mechanism. Apoptosis. 2013 Apr;18(4):480-91. doi: 10.1007/s10495-012-0800-8.
10 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
11 Formation of Mallory body-like inclusions and cell death induced by deregulated expression of keratin 18. Mol Biol Cell. 2002 Oct;13(10):3441-51. doi: 10.1091/mbc.01-10-0510.
12 Griseofulvin has a potential to modulate the expression of cell adhesion molecules on leukocytes and vascular endothelial cells. Int Immunopharmacol. 2001 Jan;1(1):75-83. doi: 10.1016/s0162-3109(00)00266-6.
13 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
14 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
15 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
16 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
17 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
20 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
22 Busfield D, Child KJ, Atkinson RM, Tomich EG "An effect of phenobarbitone on blood-levels of griseofulvin in man." Lancet 2 (1963): 1042-3. [PMID: 14062729]
23 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
24 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
25 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
26 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
27 Cerner Multum, Inc. "Australian Product Information.".
28 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
29 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
30 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
31 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
32 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
33 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
34 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
35 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
36 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
37 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
38 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
39 Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58. [PMID: 4397794]
40 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
41 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
42 Cote J "Interaction of griseofulvin and oral contraceptives." J Am Acad Dermatol 22 (1990): 124-5. [PMID: 2298948]
43 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
44 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
45 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
46 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
47 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
48 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
49 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
50 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
51 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
52 Benetello P, Furlanut M "Primidone-carbamazepine interaction: clinical consequences." Int J Clin Pharmacol Res 7 (1987): 165-8. [PMID: 3583497]
53 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
54 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
55 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
56 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
57 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
58 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
59 Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
60 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
61 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
62 Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
63 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
64 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
65 Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870]
66 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
67 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
68 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
69 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
70 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
71 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
72 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
73 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
74 Cerner Multum, Inc. "Canadian Product Information.".
75 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
76 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
77 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
78 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
79 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
80 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
81 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
82 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
83 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
84 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
85 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
86 Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
87 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
88 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
89 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
90 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
91 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
92 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
93 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
94 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
95 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
96 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
97 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
98 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
99 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
100 Phillips KR, Wideman SD, Cochran EB, Becker JA "Griseofulvin significantly decreases serum salicylate concentrations." Pediatr Infect Dis J 12 (1993): 350-2. [PMID: 8483633]
101 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
102 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
103 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
104 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
105 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
106 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
107 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
108 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
109 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
110 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
111 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
112 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
113 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
114 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
115 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
116 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
117 Canadian Pharmacists Association.
118 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
119 Product Information. Victoza (liraglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
120 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
121 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
122 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.